HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Solifenacin is effective for the treatment of OAB dry patients: a pooled analysis.

AbstractOBJECTIVE:
The aim of this analysis was to determine the effects of solifenacin in patients considered overactive bladder (OAB) dry at baseline.
METHODS:
This was a pooled analysis of 4 randomized, placebo-controlled 12-week, phase 3 studies. Patients received placebo or solifenacin 10 mg once daily (2 studies), or placebo or solifenacin 5 mg or 10 mg once daily (2 studies). A subgroup of patients without incontinence at baseline was identified from a 3-day diary. Mean changes from baseline to endpoint for urgency episodes, micturition, frequency and nocturia episodes per 24 hours, and volume voided/micturition were evaluated. The proportion of patients with normalization of micturition frequency (<8 micturitions), resolution of urgency, or resolution of nocturia at endpoint was also determined.
RESULTS:
Of 2848 evaluable patients treated with placebo or solifenacin, 975 (34%) were OAB dry at baseline. Solifenacin 5 mg and 10 mg were significantly (p < 0.001) more effective than placebo for improving urgency, micturition frequency, and volume voided. In addition, solifenacin 10mg was significantly (p < 0.01) more effective than placebo for improving nocturia. Resolution of urgency occurred significantly (p < 0.05) more often with solifenacin 5 mg (37%) and 10 mg (33%) than with placebo (25%). Significantly (p < 0.01) more OAB dry patients had normalization of micturition frequency with solifenacin 5 mg (29%) and 10 mg (35%) compared with placebo (19%). Resolution of nocturia occurred in 14%, 21%, and 13% of patients treated with solifenacin 5mg, solifenacin 10 mg, and placebo, respectively (p < 0.01 for solifenacin 10 mg versus placebo).
CONCLUSION:
Solifenacin significantly improved urgency, frequency, and nocturia symptoms and increased volume voided in OAB dry patients.
AuthorsPaul Abrams, Steven Swift
JournalEuropean urology (Eur Urol) Vol. 48 Issue 3 Pg. 483-7 (Sep 2005) ISSN: 0302-2838 [Print] Switzerland
PMID16005564 (Publication Type: Journal Article, Meta-Analysis, Research Support, Non-U.S. Gov't)
Chemical References
  • Quinuclidines
  • Tetrahydroisoquinolines
  • Solifenacin Succinate
Topics
  • Adult
  • Clinical Trials, Phase III as Topic
  • Female
  • Humans
  • Male
  • Middle Aged
  • Quinuclidines (administration & dosage, therapeutic use)
  • Randomized Controlled Trials as Topic
  • Solifenacin Succinate
  • Tetrahydroisoquinolines (administration & dosage, therapeutic use)
  • Treatment Outcome
  • Urinary Incontinence (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: